ada glp 1 recommendations The pharmacological management of Type 2 Diabetes, adapted from 2025 guidelines, focusing on treatment initiation and intensification based on patient comorbidities and glycemic control Criteria for recommendation of SGLT2

Heres the realistic timeline: Phase 3 trials (AMAZE program): - AMAZE 1 (obesity) started February 2026, enrolling ~1,150 participants - Primary completion estimated: June 2029 - Phase 3 in T2D also being planned following the ADA 2026 data US FDA approval (projected): Q4 2030 at the earliest (GlobalData estimate) EU EMA approval (projected): Q1 2031 at the earliest Bulgaria and Eastern Europe: Typically 612 months after EMA approval for market access, depending on national reimbursement negotiations

Bacteriostatic Water for Injection must never be injected on its own without being used to dissolve or dilute a medication

Trauma: A direct blow to the knee, such as in a fall or collision, can cause a tear

The treatment itself takes only a few minutes and can easily be completed during a short office visit